NCT00224081

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)

Dialysis Patients' Response to IV Iron With Elevated Ferritin

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 134 (actual)
• Sponsor: Watson Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study explores the safety and efficacy of intravenous iron therapy in anemic hemodialysis patients treated with epoetin alfa, who have higher serum ferritin levels, but low to normal transferrin saturation.

Conditions

• Anemia, Iron-Deficiency
• Kidney Failure, Chronic
• Hemodialysis

Interventions

Type	Name	Description
DRUG	Sodium ferric gluconate,	Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions

Timeline

• Start date: 2004-09-01
• Primary completion: 2006-05-01
• First posted: 2005-09-22
• Last updated: 2015-12-10

Locations

29 sites across 1 country: United States